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and Kareem M. Abll-Elmagd3 
This report investigates the influence ofliver transplantation and concomitant immunosup-
pression on the course of progression of inflammatory bowel disease (IBD) and discusses 
statistical methodology appropriate for such settings. The data on 303 patients who under-
went liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using 
person-time analysis and Cox regression, with the duration ofIBD as the time variable and 
transplantation as a segmented time-dependent covariate, to take into account both post-
transplant and pretransplant history of IBO. The need for colectomy and appearance of 
colorectal cancer were taken as outcome measures. The only significant risk factor in the 
multivariate model for colectomy was transplantation itself, which increased the risk of 
colectomy due to intractable disease (Wald statistic; P = .001). None of the variables 
available for analysis were found to influence the risk of colon cancer significantly. Graphs 
showing the dependence of the instantaneous risk of cancer on the time from onset of IBD 
and its independence from the latter in the case of colectomy are presented. The use of a 
unique statistical methodology described for the first time in this setting led us to the 
somewhat surprising conclusion that transplantation and concomitant use of immunosup-
pression accelerate the progression ofIBD. At the same time, transplantation does not affect 
the incidence of colorectal cancer. These results confirm the findings of some recent studies 
and can potentially shed new . light on the disease pathogenesis. (HEPATOLOGY 2002;35: 
380-384.) 
Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease characterized by inflammation and 
fibrosis of the biliary tree that eventually causes biliary cir-
rhosis. Despite an aSSOCIatlon between PSC and inflammatory 
bowel disease (IBD) in 55% to 75% of cases,l neither a common 
pathogenesis nor a direct cause-effect relationship for the 2 disor-
ders has been unequivocally identified. Orthotopic liver transplan-
tation (OLT) is the only definitive treatment for patients with 
advanced PSc.2 The immunosuppressive therapy needed to con-
trol rejection after transplantation is also potentially effective in 
controlling IBD3-8 except in those with refractory disease. 9 
Thus, a number of retrospective studies have attempted to de-
termine whether hepatic replacement and the concomitant use of 
different immunosuppressive regimens influences the natural his-
tory ofIBD in this unique population. lo.2o This study is unique for 
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2 reasons: (1) special emphasis was placed on the course of the 
disease before the need for hepatic replacement and (2) the applied 
statistical methodology enabled assessment of the simultaneous 
effect of multiple time-dependent factors on the outcome of in-
terest. 
Materials and Methods 
Between 1981 and 1997,303 patients underwentOLT for PSC 
at the U niversiry of Pittsburgh Medical Center. A total of 206 of 
these patients developed IBD before OL T. The date of diagnosis of 
IBD was confirmed in all study patients by histopathologic exam-
ination of tissue samples. The date of diagnosis of PSC before 
transplantation was recorded. The diagnosis ofPSC was confirmed 
in all patients by histologic examination of the hepatectomy spec-
imen removed at the time of OL T. Fourteen of the 206 patients 
with IBD underwent large bowel resection before the diagnosis of 
PSC was established. Patient demographics and transplantation 
information, including immunosuppression and survival, were re-
trieved from our computerized database. All other pertinent data, 
including the date and indication for colectomy, were obtained 
from a chart review. Follow.up data were obtained during outpa-
tient visits and from telephone interviews with the patient and/or 
primary care physicians. The study was approved by the institu-
tional review board. 
Study Population. Inclusion criteria for the studv were coex-
istence of IBD and PSC at any time before liver transplantation 
and well-documented dates of diagnoses. This information was 
required to effectively study the relationship between these diseases 
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Fig. 1. Schematic representation of key events in the modeled setting. 
Two possibilities for positioning of colectomy relative to a potential PSC 
latency period are shown. 
and liver replacement. Therefore, 14 patients who underwent co-
lectomy before the diagnosis ofPSC were excluded from the 206, 
leaving a total of 192 study cases. The only limitation imposed by 
this selection criterion, which is applicable to similar studies, was 
the undetermined delay between the actual onset of disease and the 
date of diagnosis (Fig, 1). Regardless of this, the validity of the 
resulting statistical model was unequivocally verified by repeating 
the analysis on a set including these 14 patients, 
The baseline immunosuppressive regimen included cyclospor-
ine (Novartis, East Hanover, NJ) in 96 patients (50%) and tacroli-
fiUS (Fujisawa, Deerfield, IL) in the remaining 96 patients; corti-
costeroids were used with both drugs from the outset for all 
patients, Azathioprine (Imuran; Glaxo Wellcome, Research T rian-
gle Park, NC) or more recently mycophenolate mofetil (CelICept; 
Roche Laboratories, Nutley, NJ) was used as a third drug in se-
lected cases. Thirty-seven of the 96 patients (38.5%) receiving 
cyclosporine were converted to tacrolimus at various times after 
transplantation because of acute or chronic liver allograft rejection. 
By the last date of follow-up, the patients who were administered 
tacrolimus received it for an average of 4.72 years (SO, 2.71 years); 
patients who were administered cyclosporine received it for an 
average of 5.29 years (SO, 4.77 years). Acute rejection episodes 
were treated with high doses of corticosteroids; OKT3 monoclonal 
antibody (Ortho, Raritan, NJ) was used in a few cases to treat 
severe and corticosteroid-resistant rejection. Dose adjustments of 
cyclosporine or tacrolimus were guided primarily by rejection, 
drug toxicity, and time after transplantation. The maintenance 
immunosuppressive regimen, particularly withdrawal of cortico-
steroids, was not influenced at any time during the follow-up pe-
riod by the diagnosis ofIBD. 
A total of 180 of the 192 study patients (94%) were white, and 
134 (70%) were men. IBD was predominantly ulcerative colitis 
(86%); the remaining 27 patients had either Crohn's disease or 
indeterminate pathology. P5C was diagnosed after IBD in 124 
cases. In the remaining cases, P5C was diagnosed at the same time 
(n = 21) or before (n = 47) diagnosis ofIBD. Mean age atthe time 
of diagnosis ofIBD was 31.7 years. Retransplantation was required 
for 36 primary recipients (23.5%). 
Patients not treated with complete colorectal resection were sub-
jected to a full colonoscopic examination when initially evaluated 
for OLT. Surveillance colonoscopy was performed at least everY 1 
to 2 years both before and after transplantation and more often in 
those with symptomatic disease. Indications for colorectal resec-
tion were recalcitrant or complicated disease including bleeding, 
toxic megacolon, colonic dysplasia, and colorectal cancer. Neither 
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the presence of IBD nor prior colectomy influenced the surgical 
techniques used during OL T. 
Outcome Measures. Progression of IBD before or after trans-
plantation was determined by the need for colectomy, whether due 
to clinically intractable disease, bleeding, dysplasia, or colorecral 
cancer. Because of the retrospective nature and long duration of the 
study, histopathologic documentation of colonic dysplasia was at 
best incomplete and was not included in the analysis. Because the 
aim of the study was to evaluate the effect of OLT on the natural 
progression ofIBD, time 0 in both models was the date of diagno-
sis ofIBD. 
Statistical Methods. Patients with active IBD are commonly 
treated with corticosteroids and other immunosuppressive agents 
to comrol active disease, but these agents are also well-known risk 
factors for the development of cancer, particularly among the 
transplantation population. Because of these 2 potential opposing 
influences and the current controversy concerning the risk of colo-
rectal cancer, statistical models used in this report were designed 
around the indication for colectomy. Two separate models were 
developed: one for colectomy performed because of intractable 
disease, defined as refractory IBD or bleeding, and another for 
colorectal cancer. In the former model, patients undergoing colec-
tomy for other indications (cancer, posttransplant lymphoprolif-
erative disease, or perforation) were censored. In the cancer model, 
patients who underwent colectomy for nonmalignant indications 
were censored because they were no longer at risk for the disease. 
Time 0 in both models was the date of diagnosis ofIBD. 
The predictive significance and the proportionality of hazards 
assumption for potential risk factors were investigated by univari-
ate Cox regression analysis containing the factor under consider-
ation and the same factor combined in a product with time: 
(1) 
where t is the time from the onset of IBD, h(t) is the hazard 
function, and X is the risk factor. Nonconvergent coefficients for 
variables in univariate Cox regression were tested for significance 
by person-time analysis, with CIs for incidence rate ratio calculated 
using the approximate Poisson method.21 P values less than .05 
were considered significant in multivariate analysis and in testing 
the proportional hazards assumption. 
Potential risk factors considered in univariate analysis included 
the following: age at the time of diagnosis of IBD, race, type of 
IBD, chronological order of dates of diagnosis of IBD and PSC, 
baseline immunosuppressive regimen, duration of IBD before di-
agnosis ofPSC, and time of transplantation. The univariate model 
of the immunosuppressive regimen included the type of immuno-
suppression and its product with transplantation, defined as a seg-
mented time-dependent covariate: 
{ 0 for all t before OLT Tx(t)-
- 1 for all t after OLT 
Multivariate models had the following form: 
h( t) = ho(t). p. E,' xI~ Ei·X,· f' Oi) 
(2) 
(3) 
where 0i = 0 if the proportionality of hazards assumption holds 
based on the Wald statistic for the regression coefficient in univar-
iate analysis and 1 otherwise, )( are the risk factors selected as 
.... 
I 
i. 
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Table 1. Multivariate Model of Colectomy due to 
Intractable Disease 
P Value for 
Hazard Ratio Wald 
Variable B = Exp(B) Statistic 
Age at the time of diagnosis of 
IBD (1 if older than 30 years, 
o otherwise) 0.409 1.505 .228 
OLT (segmented time-dependent 
covariate) 1.141 3.129 .001 
described above, and B;, B/ are the corresponding regression coef-
ficients. 
Results 
Mean duration of patient follow-up after OLT was 5.91 years 
(SD, 4.12 years). Post-OLT patient survival rates estimated by the 
Kaplan-Meier method at 1,5, and 10 years were 90.1%,72.7%, 
and 62.2%, respectively. Fifty-six of the 192 patients were treated 
with colectomy. The indications were refractory disease (n = 39), 
colorectal cancer (n = 13), posttransplant Iymphoproliferative dis-
ease (n = 1), and colonic perforation (n = 3). Twenty-three of the 
colectomies were performed before OL T for refractory disease 
(n = 17) or colorectal cancer (n = 6). The remaining 33 colecto-
mies were performed after OLT because of refractory disease (n = 
22), colorectal cancer (n = 7), posttransplant lymphoproliferative 
disease (n = 1), or colonic perforation (n = 3). 
For the model of colectomy due to intractable disease, only 2 
potential risk factors, age older than 30 years at the time of diag-
nosis of IBD and OLT, proved to be significant in univariate 
analysis. The multivariate Cox model is shown in Table l. Exclu-
sion of patients with retransplants did not affect the significance of 
risk factors in the analysis. Therefore, patients were retained in the 
data set regardless of the number of transplants. As shown in Table 
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Fig. 2. Cumulative pre-OlT hazard of colectomv due to intractable dis-
ease. The curve can be approximated by a straight line. indicating that the 
instantaneous hazard is distributed uniformly across duration of ISD. 
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1, OLT was the only significant risk factor for colectomy due to 
intractable disease. 
Because the latter finding was rather unexpected, the result was 
further substantiated using person-time analysis as follows. Cumu-
lative hazard of colectomy before OLT plotted against duration of 
IBD is close to a straight line (Fig. 2), which indicates that the 
distribution of instantaneous colectomy hazard is uniform relative 
to duration of IBD. With the assumption that OLT does not 
change this relationship, the incidence rates were calculated for 
colectomy before OLT by truncation of person-time at the time of 
OLT. For colectomy after OLT, accrual of person-time began on 
the date of OL T. The incidence rates for colectomy were 0.007 
before OLT and 0.025 after OLT. The incidence rate ratio was 
0.29 (95% CI, 0.15-0.54). The influence of OLT on colectomy, 
illustrated by yearly incidence rates relative to time of transplanta-
tion, is shown in Fig. 3. 
Using duration ofIBD as the time variable, univariate analysis 
showed neither OLT nor other variables to be significant risk fac-
tors for development of colon cancer after transplantation. To 
control for potential confounding influences, multivariate analysis 
using only variables previously proposed as important risk factors 
for colon cancer was performed and showed that none of these 
variables (age at time of diagnosis of IBD, OLT, and type of im-
munosuppression) were significantly associated with an increased 
risk of cancer in this model. 
The cumulative hazard of colorectal cancer as a function of 
duration of IBD before transplantation (dotted line) as well as for 
the entire IBD course (solid line) are shown in Fig. 4. In contrast to 
the hazard of colectomy for intractable disease (Fig. 2), the best fit 
for the colorectal cancer curves was an exponential function. Note 
that the increase of instantaneous hazard of cancer significantly 
depends only on the duration ofIBD. Thus, OLT does not signif-
icantly change the risk of colo recta! cancer. 
The analysis of colectomy because of intractable disease was 
repeated using several different patient cohortS in an effort to ad-
0.07 
>-
E 
0 0.06 t3 
CD (5 
u 0.05 
-0 
CD 
Cii 0.04 ~ 
CD 
U 
c: 
CD 0.03 
'0 
'13 
.!: }1r~ ;>, ~ CD >-
I 
-40 -30 -20 -10 OLTx 10 20 
Time relative to OL T (years) 
Fig. 3. Yearly incidence rates of colectomy relative to transplantation. 
Positive values on the hOrizontal axis represent the number of years elapsed 
since OLT, and negative values correspond to the number of years remaining 
until OlT. 
, 
\ 
HEPATOLOGY, Vol. 35, No.2, 2002 
0.7 
I I General (observed) a; 0.6 
I --General (exp.appr.) 
I 
() 
c 
I 
.. Pre-OL T (observed) Ol () 
0.5 .. Pre-OL T (exp.appr.) c 
0 
-0 
() 0.4 
... / 
-0 
'0 0 
co 03 ./ N f/O Ol 
::r: / 
OJ 0.2 /'0 > ~ ~ 
'S 
E 0.1 0°/' 
::J 
0 K~"KDK 
0.0 
0 5 10 15 20 25 30 35 
Time from IBD diagnosis (years) 
Fig. 4. Cumulative hazard of colorectal cancer (before transplantation 
and total) relative to the corresponding duration of IBD approximated by 
minimization of sum of squares. Exponential approximations, which had the 
best fit compared with other functional forms, are shown. 
dress possible clinical and statistical concerns. Neither inclusion of 
the 14 patients who underwent colectomy before the diagnosis of 
PSC nor inclusion of all patients who underwent colectomy af-
fected the results reported. These additional analyses further sub-
stantiate the conclusion that OLT is the only significant risk factor 
for colectomy performed because of intractable disease. 
Discussion 
The natural history of IBO and the interrelationship between 
PSC and IBO is well documented in several large series.22,23 Co-
lectomy is a well-accepted marker of progression ofIBO, and du-
ration of disease is the single most important risk factor for the 
development of colorectal cancer.24,25 Therefore, the study design 
and statistical methods used in our analyses follow the well-ac-
cepted biological evolution of the diseases and associated clinical 
end points. Missing data on colonic dysplasia is the only potential 
pitfall of this study, but it is not likely to significantly influence the 
results because the reason for colectomy was clearly documented in 
all cases. Moreover, we did not find any negative impact of trans-
plantation on the ultimate expression of the colonic dysplasia 
(colorectal cancer). Therefore, it is very unlikely that the posttrans-
plant immunosuppressive regimen could have affected transitional 
stages toward cancer. 
Despite considerable cumulative experience with liver trans-
plantation for PSc, 10,12,14,26 controversy about the course ofIBD 
after OLT among patients with PSC is fueled by the complexity of 
the IBO-PSC syndrome and small size of patient cohortS available 
for analysis. 1O.12,14 The comparatively large sample size and the 
statistical methodology used for the first time in this setting led us 
to the somewhat surprising conclusion that OLT and concomitant 
Use of immunosuppression accelerate progression of IBO. These 
results confirm the findings of some recent studies l4,ls and can 
potentially shed new light on disease pathogenesis. Studies on ex-
perimental animals show that interleukin (IL)-10-, IL-2-, or 
TCR-2- deficient mice develop IBD but only after exposure to 
enVlronmental organisms/antigens.27 A possible inference would 
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be that IBD develops in genetically susceptible individuals after 
exposure to enteric antigens, similar to humans. In susceptible 
mice, aberrant hyperresponsive C04+ T cells producing an abun-
dance ofTH1 (interferon gamma, lL- I:?) or TH2 (IL-4) cytokines 
produce lesions similar to Crohn's disease and ulcerative colitis, 
respectively.27 Thus, it could be speculated that the immunosup-
pression associated with OLT might enhance the growth of enteric 
organisms/antigens, such as cytomegalovirus, which has recently 
been implicated in refractory lBD. 9 Alternatively, it could be spec-
ulated that immunosuppression with calcineurin inhibitors prompts 
physicians to discontinue other anti-inflammatory drugs including 
daily treatment with corticosteroids, a practice that might poten-
tiate IBO in some of the patients. 
In contrast to earlier publications,13,18,19 this study found no 
significant increase in the risk of colorectal cancer after 0 L T. Our 
data show that duration of disease is the only significant risk factor 
for the development of colorectal cancer either before or after 
OL T. One possible explanation for the increased hazard of colo-
rectal cancer found in some studies is the prolonged patient sur-
vival and duration ofIBO after OL T.26 Additionally, occult ma-
lignancy at the time of transplantation cannot be excluded, 
particularly for patients who developed the disease shortly after 
transplantation. Therefore, a yearly surveillance colonoscopy is 
recommended for patients with long-standing IBD before and 
after OLT. 
In conclusion, this study shows that hepatic transplantation 
accelerates progression of IBO in patients with PSC but poses no 
additional risk for the development of colorectal cancer other than 
that determined solely by duration ofIBO. In addition, the nega-
tive impact of OLT and possibly of the use of immunosuppression 
on the course of IBD suggests that nonautoimmune mechanisms 
might well contribute to the IBD-PSC syndrome. Current contro-
versies over the course ofIBO after 0 L T may be resolved by use of 
statistical methodology that takes into account the simultaneous 
effects of multiple time-dependent factors on the outcome of in-
terest. 
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